masdegliptin

Masdegliptin is an investigational agent identified in clinical trial contexts as a glucagon-like peptide-1 (GLP-1) receptor agonist. It is currently being evaluated as an adjunctive therapy for the treatment of obesity, specifically to address the weight loss plateau observed in patients following laparoscopic sleeve gastrectomy (LSG). In this clinical setting, it is compared against other established GLP-1 receptor agonists and dual agonists, such as semaglutide and tirzepatide, to assess its impact on 12-month weight loss, metabolic parameters, and quality of life. While the name follows the nomenclature typically reserved for dipeptidyl peptidase-4 (DPP-4) inhibitors (the "-gliptin" suffix), its clinical application and trial grouping categorize it as a GLP-1 receptor agonist.

Other names

masdegliptin